CC
LXEO icon

Caxton Corporation’s Lexeo Therapeutics LXEO Stock Holding History

Caxton Corporation’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79K Buy
16,962
+3,019
+22% +$16.3K 4.26% 7
2026
Q1 		$80K Hold
13,943
– – 1.99% 4
2025
Q4 		$138K Sell
13,943
-3,389
-20% -$30.9K 3.24% 7
2025
Q3 		$115K Hold
17,332
– – 0.5% 9
2025
Q2 		$69.7K Sell
17,332
-519
-3% -$1.71K 0.71% 9
2025
Q1 		$61.9K Hold
17,851
– – 1.22% 7
2024
Q4 		$117K Hold
17,851
– – 0.71% 8
2024
Q3 		$161K Hold
17,851
– – 0.67% 7
2024
Q2 		$286K Buy
17,851
+7,532
+73% +$109K 1.45% 5
2024
Q1 		$162K Hold
10,319
– – 0.92% 9
2023
Q4 		$138K Buy
+10,319
New +$128K 0.75% 9

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Caxton Corporation's LXEO Position: Q2 2026 in Review

Caxton Corporation increased its Lexeo Therapeutics (LXEO) stake by 22% in Q2 2026, buying an estimated $16.3K and bringing the position to 16,962 shares worth $79K. The position accounts for 4.26% of the portfolio, ranked #7.

Caxton Corporation first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $286K in Q2 2024. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Caxton Corporation held 16,962 shares of Lexeo Therapeutics worth $79K as of Q2 2026.
  • Caxton Corporation bought 3,019 Lexeo Therapeutics shares in Q2 2026, an estimated $16.3K.
  • Lexeo Therapeutics made up 4.26% of Caxton Corporation's portfolio in Q2 2026, its #7 holding.
  • Caxton Corporation first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Caxton Corporation's Lexeo Therapeutics position peaked at $286K in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Caxton Corporation's 13F filing for Q2 2026, filed 14 Aug 2026.